Walgreens was subject to a serious investigation by the Drug Enforcement Administration after committing dispensing and record-keeping violations. The company is now paying $80 million in fines for allowing controlled substances such as oxycodone to reach the black market. The company's Jupiter, Florida distribution center was at the center of the allegations and the DEA suspended the center's controlled substance license until September 2014. The DEA also suspended the licenses of six more Walgreens Florida distribution centers until May 2014. Walgreens has cooperated in improving the inventory systems at the distribution centers and working with employees to educate them on how to properly dispense controlled substances. Other pharmacies are subject to similar investigations, including CVS and Cardinal Health. One of the issues at the center of the Walgreens investigation was the company's failure to report suspicious and high-quantity orders of controlled substances. The company is required to notify the DEA of these incidents. Several Florida Walgreens locations ordered more than 1 million oxycodone pills a year, when the average is only about 73,000. Cases such as those are clear instances where pharmacists are ignoring suspicious signs and failing to properly notify the DEA.